These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

81 related articles for article (PubMed ID: 3652460)

  • 1. A haemolytic assay for the measurement of C9 in human serum and cerebrospinal fluid.
    Asghar SS; Siem H; van der Helm HJ
    Clin Chim Acta; 1987 Jun; 165(2-3):387-90. PubMed ID: 3652460
    [No Abstract]   [Full Text] [Related]  

  • 2. Terminal component of complement (C9) in cerebrospinal fluid of patients with multiple sclerosis.
    Morgan BP; Campbell AK; Compston DA
    Lancet; 1984 Aug; 2(8397):251-4. PubMed ID: 6146808
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Terminal component of complement (C9) in the cerebrospinal fluid of patients with multiple sclerosis and neurologic controls.
    Rodriguez M; Wynn DR; Kimlinger TK; Katzmann JA
    Neurology; 1990 May; 40(5):855-7. PubMed ID: 2330118
    [TBL] [Abstract][Full Text] [Related]  

  • 4. On the cause and nature of C9-related heterogeneity of terminal complement complexes generated on target erythrocytes through the action of whole serum.
    Bhakdi S; Tranum-Jensen J
    J Immunol; 1984 Sep; 133(3):1453-63. PubMed ID: 6747293
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Species-restricted target cell lysis by human complement: complement-lysed erythrocytes from heterologous and homologous species differ in their ratio of bound to inserted C9.
    Hu VW; Shin ML
    J Immunol; 1984 Oct; 133(4):2133-7. PubMed ID: 6470486
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunoradiometric assay for human complement component C9 utilising monoclonal antibodies.
    Morgan BP; Campbell AK; Luzio JP; Siddle K
    Clin Chim Acta; 1983 Oct; 134(1-2):85-94. PubMed ID: 6652914
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lytic activity of C5-9 complexes for erythrocytes from the species other than sheep: C9 rather than C8-dependent variation in lytic activity.
    Yamamoto KI
    J Immunol; 1977 Oct; 119(4):1482-5. PubMed ID: 894048
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Complement lysis of human erythrocytes. II. A unique interaction of human C8 and C9 with paroxysmal nocturnal hemoglobinuria erythrocytes.
    Packman CH; Rosenfeld SI; Jenkins DE; Leddy JP
    J Immunol; 1980 Jun; 124(6):2818-23. PubMed ID: 7189536
    [No Abstract]   [Full Text] [Related]  

  • 9. Haemolytic complement in peripheral lymph of normal men.
    Olszewski WL; Engeset A
    Clin Exp Immunol; 1978 Jun; 32(3):392-8. PubMed ID: 99278
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Measurement of the ratio of the eighth and ninth components of human complement on complement-lysed membranes.
    Stewart JL; Monahan JB; Brickner A; Sodetz JM
    Biochemistry; 1984 Aug; 23(18):4016-22. PubMed ID: 6487588
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Studies on the terminal stages of immune hemolysis. III. Distinction between the insertion of C9 and the formation of a transmembrane channel.
    Boyle MD; Langone JJ; Borsos T
    J Immunol; 1978 May; 120(5):1721-25. PubMed ID: 659873
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molecular composition of the terminal membrane and fluid-phase C5b-9 complexes of rabbit complement. Absence of disulphide-bonded C9 dimers in the membrane complex.
    Bhakdi S; Tranum-Jensen J
    Biochem J; 1983 Mar; 209(3):753-61. PubMed ID: 6870789
    [TBL] [Abstract][Full Text] [Related]  

  • 13. C5b-9 assembly: average binding of one C9 molecule to C5b-8 without poly-C9 formation generates a stable transmembrane pore.
    Bhakdi S; Tranum-Jensen J
    J Immunol; 1986 Apr; 136(8):2999-3005. PubMed ID: 3958488
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Quantitative measurement of C9 sites and their association to the ring-like "lesions" on complementlysed membranes: a morphometric immunoferritin study.
    Rauterberg EW; Ungemach B; Gebest HJ
    J Immunol; 1979 Jan; 122(1):355-65. PubMed ID: 570204
    [No Abstract]   [Full Text] [Related]  

  • 15. [C6, C7, C8 and C9].
    Hatanaka M; Kitano E
    Nihon Rinsho; 2010 Jun; 68 Suppl 6():90-3. PubMed ID: 20942009
    [No Abstract]   [Full Text] [Related]  

  • 16. Activation of the fifth and sixth component of the complement system: similarities between C5b6 and C(56)a with respect to lytic enhancement by cell-bound C3b or A2C, and species preferences of target cell.
    Hänsch GM; Hammer CH; Mayer MM; Shin ML
    J Immunol; 1981 Sep; 127(3):999-1002. PubMed ID: 6911149
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibition of the lytic action of cell-bound terminal complement components by human high density lipoproteins and apoproteins.
    Rosenfeld SI; Packman CH; Leddy JP
    J Clin Invest; 1983 Apr; 71(4):795-808. PubMed ID: 6403580
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A high incidence of C9 deficiency among healthy blood donors in Osaka, Japan.
    Fukumori Y; Yoshimura K; Ohnoki S; Yamaguchi H; Akagaki Y; Inai S
    Int Immunol; 1989; 1(1):85-9. PubMed ID: 2487678
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Paroxysmal nocturnal haemoglobinuria with coexisting deficiency of the ninth component of complement: lack of massive haemolytic attack.
    Yonemura Y; Kawakita M; Koito A; Kawaguchi T; Nakakuma H; Kagimoto T; Schichishima T; Terasawa T; Akagaki Y; Inai S
    Br J Haematol; 1990 Jan; 74(1):108-13. PubMed ID: 2310692
    [TBL] [Abstract][Full Text] [Related]  

  • 20. 1,10-Phenanthroline mediated hemolysis--evidence that 1,10-phenanthroline does not substitute specifically for C9.
    Boyle MD; Langone JJ; Borsos T
    Mol Immunol; 1979 May; 16(5):307-12. PubMed ID: 40111
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.